Eli Lilly and Company

Eli Lilly and Company

1,347.11
USD
-4.01
(-0.30%)
30.81EPS
37.45P/E
1.03TMarket Cap
Feb 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
20.7
17.66
18.06
19.28
18.99
20.91
23.31
25.65
29.69
30.04
37.94
50.19
72.84
96.85
Basic EPS, GAAP
4.19
2.15
2.18
2.49
-0.19
3.14
8.69
6.47
5.85
6.57
5.83
11.8
23.07
30.89
Free Cash Flow per Basic Share
4.16
2.6
1.21
3.41
3.28
2.44
3.64
4.67
5.65
4.84
-3.5
0.46
6.67
13.09
Dividend per Share
1.9
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.24
3.72
4.52
5.21
6.02
6.7
Book Value per Share
15.79
13.84
13.18
12.72
10.54
9.3
2.72
5.9
9.42
11.21
11.98
15.81
29.65
45.19
Tangible Book Value per Share
11.91
9.66
4.97
5.16
2.9
7
-8.03
-5.83
-2.73
-0.66
-1.19
2.51
15.77
13.82
Basic Weighted Avg Shares
1,117
1,111
1,105
1,101
1,052
1,028
958
957
954
950
899
898
895
893
Sales/Revenue/Turnover
23,113
19,616
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
86,462
Operating Margin (%)
24
16.97
18
17.31
20.03
26.92
25.94
28.36
26.99
29.01
30.26
37.83
45.56
51.25
Depreciation Expense
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,523
1,527
1,767
1,997
2,174
Net Income, GAAP
4,685
2,391
2,408
2,738
-204
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
27,580
Effective Tax Rate (%)
20.45
20.32
13.68
18.86
103.75
14.39
11.93
14.33
9.32
8.25
20.05
16.48
19.79
20.68
Profit Margin (%)
20.27
12.19
12.07
12.9
-1.02
15.04
37.27
25.24
19.71
21.88
15.36
23.51
31.67
31.9
Working Capital
4,188
2,187
4,344
4,115
4,666
8,662
1,934
4,981
3,400
896
-1,566
4,364
20,401
18,267
LT Debt
4,200
5,333
7,972
8,368
9,941
9,196
13,818
16,587
15,346
14,738
18,321
28,527
40,868
46,986
Total Equity
17,641
15,388
14,590
14,081
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
40,271
Return on Invested Capital (%)
18.89
8.69
9.11
10.48
-0.3
12.77
22.31
25.29
22.01
24.39
16.25
25.66
36.08
33.42
Return on Capital (%)
22.3
10.85
11.08
12.3
-0.86
14.79
44.21
32.16
24.31
24.69
17.84
26.76
35.3
35.33
Return on Common Equity (%)
28.92
14.49
16.09
19.16
-1.59
30.18
133.78
150.18
76.35
63.63
48.92
84.84
101.36
86.1

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
4,000
7,050
2,517
LT Borrowings
39,370
47,858
46,986
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
894
892
891
Market Capitalization
821,814
1,069,292
1,031,190

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
54,835
64,672
65,263
Cash, Cash Equivalents & STI
5,282
8,950
4,885
Accounts Receivable, Net
18,429
20,083
22,089
Inventories
14,529
16,793
18,194
Total Current Liabilities
36,634
47,741
46,996
Payables & Accruals
22,576
27,234
29,963
ST Debt
4,000
7,050
2,517
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.64%
38.59%
85.92%
Free Cash Flow
127.74%
212.97%
1,340.58%
Net Income, GAAP
-146.26%
36.58%
94.9%
Sales/Revenue/Turnover
13.43%
22.49%
44.7%
Total Cash Common Dividend
9.88%
14.91%
15.04%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,768
11,303
11,439
13,533
45,043
2025
12,729
15,558
17,601
19,292
65,179
2026
19,799
22,974
24,397
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.49
3.3
1.08
4.91
11.8
2025
3.07
6.3
6.23
7.42
23.07
2026
8.28
7.96
7.24
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.3
1.3
1.3
5.21
2025
1.5
1.5
1.5
1.5
6.02
2026
1.73
1.73
1.73
- -
- -

Company Description

CEO
David A. Ricks
Full Time Employees
50,000
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Lilly Corporate Center Indianapolis IN United States 46285
IPO Date
Jul 9, 1970
Website
lilly.com
Business
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Company News

  • Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight

  • My Top Dividend Growth Picks In Each GICS Sector (November 2026)

  • Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?

  • AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?

  • Novo Nordisk Stock: The AI Case Wall Street May Be Missing

  • $1,000 Invested in Eli Lilly 10 Years Ago Would Be Worth a Fortune Today

  • Is Immunology Emerging as Eli Lilly's Next Growth Driver?

  • Eli Lilly: Everyone Losing Weight, But Lilly Keeps Gaining (Initiating With A Buy)

  • Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says

  • Worried investors are paying up for these stocks — some with up to 49% upside, analysts say

  • Eli Lilly Caught in Vendor Hack as Extortion Group Threatens to Leak Data on 1.2 Million Patients

  • Eli Lilly and Company $LLY Shares Acquired by Banco Santander S.A.

  • Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody

  • Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion

  • Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

  • Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027

  • Danske Bank A S Sells 71,588 Shares of Eli Lilly and Company $LLY

  • 2,565 Shares in Eli Lilly and Company $LLY Bought by California First Leasing Corp

  • Top 50 High-Quality Dividend Growth Stocks For November 2026

  • Bernicke Wealth Management Ltd. Makes New $5 Million Investment in Eli Lilly and Company $LLY